Once-weekly dose of 8400 IU vitamin D(3) compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency

Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. We examined the effects of a weekly dose of 8400 IU vitamin D(3) on postural stability, muscle strength, and safety. In this double-blind trial, subjects aged > or =70 y with s...

Full description

Saved in:

Bibliographic Details
Published in:	The American journal of clinical nutrition 2010-04, Vol.91 (4), p.985
Main Authors:	Lips, Paul, Binkley, Neil, Pfeifer, Michael, Recker, Robert, Samanta, Suvajit, Cohn, Dosinda A, Chandler, Julie, Rosenberg, Elizabeth, Papanicolaou, Dimitris A
Format:	Article
Language:	eng
Subjects:	Aged Aged, 80 and over Cholecalciferol - administration & dosage Dietary Supplements Double-Blind Method Drug Administration Schedule Female Humans Male Movement - drug effects Parathyroid Hormone - blood Postural Balance - drug effects Vitamin D - analogs & derivatives Vitamin D - blood Vitamin D Deficiency - blood Vitamin D Deficiency - drug therapy Vitamin D Deficiency - physiopathology Vitamins - adverse effects Vitamins - blood Vitamins - pharmacology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. We examined the effects of a weekly dose of 8400 IU vitamin D(3) on postural stability, muscle strength, and safety. In this double-blind trial, subjects aged > or =70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations < or =20 but > or =6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D(3) (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSway(PLUS) platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH)D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored. Serum 25(OH)D concentrations rose significantly (from 13.9 to 26.2 ng/mL, P < 0.001) in patients treated with 8400 IU vitamin D(3) but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (> or = 0.46 compared with
ISSN:	1938-3207